Agios Pharmaceuticals:Kendra Adams, 617-844-6407Senior Director, Investor & Public RelationsKendra.Adams@agios.comRenee Leck, 617-649-8299Senior Manager, Investor & Public RelationsRenee.Leck@agios.com
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
Obamacare? Trumpcare? These stocks don't care.
Here's how to rake in the profits off some potential big breakouts.